Reduced expression of ALKBH5 was more frequently observed in T3–T4, N1–N3, clinical stage III–IV, and histological grade III tumors than in T1–T2, N0, clinical stage I–II, and histological grade I–II tumors (Figure 1E, 1F and Table 2), indicating ALKBH5 loss as a major molecular event in advanced cases of ESCC. Here, ALKBH5 is linked to esophageal squamous cell carcinoma.